Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma ( RRMM) Patients

被引：1
|
作者：
不详
机构：
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-151161
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1616
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001
    Facon, Thierry
    Lonial, Sagar
    Weiss, Brendan M.
    Suvannasankha, Attaya
    Fay, Joseph
    Arnulf, Bertrand
    Ifthikharuddin, Jainulabdeen J.
    de Boer, Carla
    Wang, Jianping
    Wu, Kaida
    Chari, Ajai
    Lentzsch, Suzanne
    Schecter, Jordan
    Krishnan, Amrita
    BLOOD, 2017, 130
  • [22] A multicenter, randomized, phase 3 study of pomalidomide and dexamethasone (Pom-dex) with or without daratumumab in patients with relapsed or refractory multiple myeloma (RRMM): APOLLO
    Terpos, E.
    Dimopoulos, M. A.
    Kastritis, E.
    Schecter, J. M.
    Ukropec, J.
    Smith, E.
    Sonneveld, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] APOLLO: Phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Einsele, H.
    Dimopoulos, M.
    Terpos, E.
    Boccadoro, M.
    Delimpasi, S.
    Beksac, M.
    Katodritou, E.
    Moreau, P.
    Baldini, L.
    Symeonidis, A.
    Bila, J.
    Oriol, A.
    Mateos, M. -, V
    Orfanidis, I
    Ahmadi, T.
    Ukropec, J.
    Kampfenkel, T.
    Schecter, J.
    Qiu, Y.
    Amin, H.
    Vermeulen, J.
    Carson, R.
    Sonneveld, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 178 - 178
  • [24] phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Sperling, Adam
    Bianchi, Giada
    Munshi, Nikhil
    O'Donnell, Elizabeth
    Branagan, Andrew
    Avigan, David
    Liegel, Jessica
    Harrington, Cynthia
    Agyemang, Emerentia
    Lively, Kathleen
    Packer, Lisette
    Han, Samuel
    Minsky, Cole
    Riadi, Manal
    Mcvey, Cailin
    Donnelly, Kaleigh
    Smith, Caitlin
    Katzeff, Mackenna
    Goguen, Amy
    Horick, Nora
    Richardson, Paul
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S220 - S221
  • [25] MELFLUFEN THERAPY FOR HEAVILY PRETREATED RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS REFRACTORY TO DARATUMUMAB AND/OR POMALIDOMIDE: EARLY EFFICACY DATA (HORIZON)
    Mateos, M., V
    Oriol Rocafiguera, A.
    Rodriguez-Otero, P.
    Blade, J.
    Larocca, A.
    Moreb, S. J.
    Cavo, M.
    Mazumder, A.
    Alegre, A.
    Hassoun, H.
    Maisel, C.
    Paner, A.
    Gabrail, N.
    Halka, K.
    Zonder, J.
    Ocio, E.
    Byrne, C.
    Harmenberg, J.
    Lindberg, J.
    Nordstrom, E.
    Thuresson, S.
    Richardson, G. P.
    HAEMATOLOGICA, 2018, 103 : 32 - 32
  • [26] Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience
    Abdallah, Al-Ola
    Dunavin, Neil
    McClune, Brian
    Shune, Leyla
    Dias, Ajoy L.
    Mahmoudjafari, Zahra
    Hochard, Erica
    McGuirk, Joseph P.
    Ganguly, Siddhartha
    BLOOD, 2018, 132
  • [27] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Dharshan Sivaraj
    Michael M Green
    Yubin Kang
    Gwynn D Long
    David A Rizzieri
    Zhiguo Li
    Anderson H Garrett
    Jackie L McIntyre
    Nelson J Chao
    Cristina Gasparetto
    Blood Cancer Journal, 8
  • [28] Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment
    Matsue, Kosei
    Sunami, Kazutaka
    Matsumoto, Morio
    Kuroda, Junya
    Sugiura, Isamu
    Iwasaki, Hiromi
    Chung, Weiyuan
    Kuwayama, Shigeki
    Nishio, Mitsufumi
    Lee, Kim
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (01) : 122 - 130
  • [29] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Sivaraj, Dharshan
    Green, Michael M.
    Kang, Yubin
    Long, Gwynn D.
    Rizzieri, David A.
    Li, Zhiguo
    Garrett, Anderson H.
    McIntyre, Jackie L.
    Chao, Nelson J.
    Gasparetto, Cristina
    BLOOD CANCER JOURNAL, 2018, 8
  • [30] Pomalidomide, Cyclophosphamide and Dexamethasone (PCD) is an Effective Salvage Regimen for Multiple Myeloma (MM) Patients Relapsed and/or Refractory to Daratumumab
    Brioli, Annamaria
    Mancuso, Katia
    Ernst, Thomas
    Hilgendorf, Inken
    Zamagni, Elena
    Heidel, Florian
    Stauch, Thomas
    Hochhaus, Andreas
    von Lilienfeld-Toal, Marie
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 129 - 130
12345